Health X Platform Ltd
Health X Platform Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
SastaSundar estimates 100% growth in B2C segment for FY '26 compared to FY '25. - RetailerShakti B2B business nearly doubled revenue from INR489 crores in FY '24 to approx. FY '26: Targeting RetailerShakti to achieve positive EBITDA margin (~1% in the last quarter), continuing investment of INR45-50 crores in SastaSundar B2C.
From Health X Platform Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SastaSundar estimates 100% growth in B2C segment for FY '26 compared to FY '25.
- RetailerShakti B2B business nearly doubled revenue from INR489 crores in FY '24 to approx. INR941 crores in FY '25.
- Target positive EBITDA margin of 1% for RetailerShakti by Q4 FY '26.
- Aim for blended EBITDA margin between 4% to 5% by FY '30, with SastaSundar targeting 7% and RetailerShakti around 4%.
- Long-term vision to scale rapidly with a highly scalable and sustainable model.
- Focus on building innovative digital healthcare products and AI-driven tools to enhance customer engagement.
2 more points from Health X Platform Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Health X Platform Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- SastaSundar plans to invest around INR150 crores primarily in technology, supply chain, and warehouse capabilities over FY '25 and FY '26.
- In FY '25, INR35 crores were invested in the technology team and advertisement, matching projections.
- FY '26 projection includes around INR50 crores investment mainly directed towards building the technology platform and AI capabilities.
- Treasury income will cover about INR50 crores investment in SastaSundar, aiming for self-sufficiency without raising new capital for at least 2-3 years.
- Capital allocation is cautious, focusing on small-scale experiments with low failure costs for learning.
2 more points from Health X Platform Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Health X Platform Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Health X Platform Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Health X Platform Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹346 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Health X Platform's management said in earlier quarters
Others in Healthcare Services this season
- 3B Blackbio (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
- Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Suraksha Diagnostic Ltd (Q4 FY25)
Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…
Arthneeti Pro · Annual
Health X Platform Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Health X Platform Ltd Q4 FY25 results?
SastaSundar estimates 100% growth in B2C segment for FY '26 compared to FY '25. - RetailerShakti B2B business nearly doubled revenue from INR489 crores in FY '24 to approx. FY '26: Targeting RetailerShakti to achieve positive EBITDA margin (~1% in the last quarter), continuing investment of INR45-50 crores in SastaSundar B2C.
What is Health X Platform Ltd share price analysis?
Health X Platform Ltd currently shows a neutral. The stock trades at a P/E of 508.6 with a market cap of ₹977 Cr. Investors should review the full earnings analysis for detailed insights.
Is Health X Platform Ltd planning capital expenditure?
SastaSundar plans to invest around INR150 crores primarily in technology, supply chain, and warehouse capabilities over FY '25 and FY '26.
Keep Health X Platform Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.